# Search concepts for the living review of GLP-1 receptor agonist containing drugs.
#
# One file defines every term once. R/search_strategy.R renders it into the
# native syntax of each source, and every run writes the rendered query next to
# its results, so the exact string sent to each API is always on record.
#
# version: bumped whenever a term is added or removed. A change is a protocol
# amendment and is logged in protocol/amendments.csv.
version: 1.1.0
date: 2026-10-12
# 1.1.0 (protocol 0.2.0, peer review round 1): mechanism block, new agents and
# development codes, HRS9531 and HRS-7535 separated, taspoglutide codes.

intervention:
  # Class level terms. Phrases are searched as phrases; a trailing * truncates
  # where the source supports it and is dropped where it does not.
  class:
    - "glucagon-like peptide-1 receptor agonist*"
    - "glucagon-like peptide 1 receptor agonist*"
    - "glucagon like peptide 1 receptor agonist*"
    - "GLP-1 receptor agonist*"
    - "GLP-1R agonist*"
    - "GLP-1 RA"
    - "GLP-1 RAs"
    - "GLP-1RA*"
    - "GLP1RA*"
    - "GLP-1 agonist*"
    - "GLP1 agonist*"
    - "GLP-1 analog*"
    - "GLP-1 analogue*"
    - "glucagon-like peptide-1 analog*"
    - "glucagon-like peptide-1 analogue*"
    - "incretin mimetic*"
    - "incretin-based therap*"
    - "incretin based therap*"
    - "GIP/GLP-1 receptor agonist*"
    - "GLP-1/GIP receptor agonist*"
    - "GLP-1/glucagon receptor agonist*"
    - "glucagon/GLP-1 receptor agonist*"

  # Agents: generic names, brand names and development codes. Each agent maps
  # to a node family in protocol/nodes.csv.
  agents:
    semaglutide: [semaglutide, Ozempic, Wegovy, Rybelsus, NN9535, "NN-9535", NN9536, "NN-9536", NN9924, "NNC0113-0217"]
    liraglutide: [liraglutide, Victoza, Saxenda, NN2211, "NN-2211", "NNC 90-1170"]
    dulaglutide: [dulaglutide, Trulicity, LY2189265]
    exenatide: [exenatide, Byetta, Bydureon, exendin-4, "exendin 4", AC2993, "AC 2993", "ITCA 650", ITCA650]
    lixisenatide: [lixisenatide, Lyxumia, Adlyxin, AVE0010, "AVE 0010"]
    albiglutide: [albiglutide, Tanzeum, Eperzan]
    taspoglutide: [taspoglutide, R1583, BIM51077]
    efpeglenatide: [efpeglenatide, HM11260C]
    beinaglutide: [beinaglutide]
    noiiglutide: [noiiglutide, SHR20004]
    pb119: ["PB-119", PB119]
    loxenatide: [loxenatide, "PEG-loxenatide", "polyethylene glycol loxenatide"]
    ecnoglutide: [ecnoglutide, XW003]
    supaglutide: [supaglutide]
    efsubaglutide: [efsubaglutide]
    glutazumab: [glutazumab, GMA102]
    bofanglutide: [bofanglutide, GZR18]
    dapiglutide: [dapiglutide]
    tirzepatide: [tirzepatide, Mounjaro, Zepbound, LY3298176]
    retatrutide: [retatrutide, LY3437943]
    survodutide: [survodutide, "BI 456906", BI456906]
    mazdutide: [mazdutide, IBI362, LY3305677]
    cotadutide: [cotadutide, MEDI0382]
    efinopegdutide: [efinopegdutide, "MK-6024", HM12525A]
    pemvidutide: [pemvidutide, "ALT-801"]
    orforglipron: [orforglipron, LY3502970]
    danuglipron: [danuglipron, "PF-06882961"]
    lotiglipron: [lotiglipron, "PF-07081532"]
    aleniglipron: [aleniglipron, "GSBR-1290"]
    # Cagrilintide alone is an amylin analogue; it is searched because CagriSema
    # trials randomize cagrilintide monotherapy arms and describe the
    # combination as cagrilintide plus semaglutide.
    cagrilintide_semaglutide: [CagriSema, cagrilintide, AM833, "NNC0174-0833"]
    amycretin: [amycretin]
    maridebart_cafraglutide: [maridebart, MariTide, "AMG 133"]
    vk2735: [VK2735]
    hrs9531: [HRS9531, "HRS-9531"]
    hrs7535: ["HRS-7535", HRS7535]
    efocipegtrutide: [efocipegtrutide, HM15211]
    ubt251: [UBT251, "UBT-251"]
    zenagamtide: [zenagamtide]
    dr10624: [DR10624, "DR-10624"]
    ct388: ["CT-388", CT388]
    hs20094: ["HS-20094", HS20094]
    insulin_degludec_liraglutide: [IDegLira, Xultophy, "insulin degludec/liraglutide"]
    insulin_glargine_lixisenatide: [iGlarLixi, Soliqua, Suliqua, "insulin glargine/lixisenatide", LixiLan]
    insulin_icodec_semaglutide: [IcoSema, "insulin icodec/semaglutide"]

  # Mechanism block: catches agents named only by mechanism, including new
  # molecules not yet in the agent list. Rendered as (mechanism) AND (context).
  # Version 1.1.0 test: 190 PubMed records not retrieved by the rest of the
  # strategy, including trials of UBT251, zenagamtide and DR10624.
  mechanism:
    - "dual agonist*"
    - "triple agonist*"
    - "tri-agonist*"
    - "polyagonist*"
    - "incretin agonist*"
    - "co-agonist*"
    - "coagonist*"
    - "unimolecular"
  mechanism_context:
    - "GLP-1"
    - "GLP1"
    - "glucagon-like peptide"
    - "glucagon"
    - "GIP"
    - "incretin*"
    - "amylin"

  # Controlled vocabulary, PubMed only. Scope is therapeutic drugs, so the
  # endogenous hormone heading ("Glucagon-Like Peptide 1") is left out: on
  # 2026-10-12 it added 6,988 records not otherwise retrieved, mostly
  # physiology, of which 484 were infusion experiments of native GLP-1 in
  # humans (outside scope; see protocol). "Glucagon-Like Peptide-1
  # Receptor/agonists"[Mesh] added 0 records and is covered.
  pubmed_mesh:
    - '"Glucagon-Like Peptide-1 Receptor Agonists"[Mesh]'
    - '"Glucagon-Like Peptide-1 Receptor Agonists"[pa]'
    - '"Liraglutide"[Mesh]'
    - '"Exenatide"[Mesh]'
    - 'semaglutide[nm]'
    - 'tirzepatide[nm]'
    - 'dulaglutide[nm]'
    - 'lixisenatide[nm]'
    - 'albiglutide[nm]'
    - 'taspoglutide[nm]'
    - 'efpeglenatide[nm]'
    - 'survodutide[nm]'
    - 'insulin degludec, liraglutide drug combination[nm]'
    - 'insulin glargine, lixisenatide drug combination[nm]'

# Chinese names for manual searches of CNKI and Wanfang Data. To be verified
# by a Chinese-reading team member before the first search; additions are
# logged in protocol/amendments.csv like any other term.
chinese_terms:
  class: ["GLP-1受体激动剂", "胰高血糖素样肽-1受体激动剂"]
  agents:
    semaglutide: ["司美格鲁肽"]
    liraglutide: ["利拉鲁肽"]
    dulaglutide: ["度拉糖肽"]
    exenatide: ["艾塞那肽"]
    lixisenatide: ["利司那肽"]
    beinaglutide: ["贝那鲁肽"]
    loxenatide: ["洛塞那肽"]
    tirzepatide: ["替尔泊肽"]
    mazdutide: ["玛仕度肽"]

# No design, language or date limits are applied at the search stage. Every
# record is classified afterwards (R/classify.R) so that the inventory keeps
# trials, observational studies, systematic reviews and protocols alike.
limits: none